Transport
Sanford Bismarck
Sanford Bismarck was paid $12.50M by Medicaid between Jan 2018 and Dec 2024, across 169 billing codes. Its largest line is 99284, emergency room visit (serious) — 30% of everything it billed.
33Billing provider infoSANFORD BISMARCK
BISMARCK, ND 58501
BISMARCK, ND 58501
33aNPI1538245634assigned 10/31/2006
33bProvider typeAir Ambulance
28Total paid$12.50M
24GClaims222,297
24DCodes billed169
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MORRISON, TONY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 53,315 | $1.64M | |
| 2019 | 21,593 | $1.41M | |
| 2020 | 18,325 | $1.11M | |
| 2021 | 33,162 | $1.91M | |
| 2022 | 27,034 | $2.00M | |
| 2023 | 38,070 | $2.58M | |
| 2024incomplete | 30,798 | $1.86M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 14,855 | 13,844 | $3.71M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 16,823 | 15,878 | $3.04M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.3% | 3,760 | 3,520 | $1.03M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 6.5% | 9,981 | 3,076 | $813K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 5.8% | 17,746 | 4,339 | $719K |
| 62323 | 5.6% | 1,374 | 1,308 | $702K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.5% | 15,621 | 11,914 | $310K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 2.4% | 464 | 349 | $296K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.2% | 2,364 | 2,082 | $277K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.9% | 7,748 | 2,472 | $239K |
| 20553 | 1.3% | 1,754 | 1,643 | $163K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 7,469 | 6,976 | $155K |
157 more codes
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 817 | $113K |
| G0378 | Hospital observation service, per hour | <1% | 398 | $105K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 200 | $96K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 100 | $83K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 160 | $65K |
| 36415 | Collection of venous blood by venipuncture | <1% | 23,052 | $65K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 920 | $47K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,059 | $45K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,231 | $44K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 232 | $38K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 52 | $26K |
| 80053 | Comprehensive metabolic panel | <1% | 19,223 | $21K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 439 | $21K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,200 | $19K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 316 | $18K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,393 | $16K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 770 | $13K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 52 | $12K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 16 | $11K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 22 | $11K |
| 19083 | <1% | 12 | $10K | |
| 97116 | <1% | 538 | $9K | |
| 97161 | <1% | 188 | $9K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 48 | $9K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 264 | $9K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,107 | $9K |
| 0240U | <1% | 84 | $8K | |
| 71045 | Radiologic examination, chest; single view | <1% | 634 | $8K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 169 | $7K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 222 | $7K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 22,171 | $7K |
| 97113 | <1% | 82 | $5K | |
| 92523 | <1% | 28 | $5K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 88 | $5K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,818 | $4K |
| 84439 | <1% | 344 | $4K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 117 | $4K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 13 | $4K |
| 73630 | <1% | 125 | $3K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 151 | $3K |
| 97162 | <1% | 48 | $3K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 497 | $3K |
| 76942 | <1% | 214 | $3K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 67 | $2K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 873 | $2K |
| 81001 | <1% | 2,557 | $2K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 1,263 | $2K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 45 | $2K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 1,480 | $2K |
| 80061 | Lipid panel | <1% | 322 | $2K |
| 76642 | <1% | 14 | $2K | |
| 94060 | <1% | 36 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,772 | $1K |
| 85027 | <1% | 413 | $1K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 15 | $1K |
| 94729 | <1% | 32 | $1K | |
| C1769 | Guide wire | <1% | 17 | $1K |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 268 | $1K |
| 93970 | <1% | 19 | $934.83 | |
| 77065 | Tomosynthesis, mammo | <1% | 12 | $927.56 |
| 20610 | <1% | 69 | $925.55 | |
| 80069 | <1% | 90 | $914.89 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 334 | $834.14 |
| 97165 | <1% | 17 | $804.43 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,033 | $737.95 |
| 82533 | <1% | 34 | $730.34 | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 26 | $694.71 |
| 83970 | <1% | 32 | $649.54 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 52 | $644.92 |
| 86850 | <1% | 120 | $602.22 | |
| J2359 | Injection, olanzapine, 0.5 mg | <1% | 63 | $552.41 |
| 82077 | <1% | 856 | $486.08 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 14 | $460.18 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 629 | $455.49 |
| 83655 | <1% | 49 | $448.32 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 325 | $367.93 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,289 | $354.12 |
| 73562 | <1% | 35 | $345.28 | |
| 73610 | <1% | 33 | $321.58 | |
| 86140 | <1% | 3,112 | $311.35 | |
| 88304 | <1% | 21 | $304.10 | |
| 73030 | <1% | 64 | $296.10 | |
| 86780 | <1% | 39 | $271.02 | |
| 87150 | <1% | 13 | $257.29 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 86 | $240.91 |
| 82570 | <1% | 117 | $230.44 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 23 | $174.53 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,087 | $173.63 |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 14 | $160.79 |
| 83735 | <1% | 1,193 | $137.23 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,854 | $134.55 |
| 84484 | <1% | 924 | $120.72 | |
| 83690 | <1% | 880 | $110.08 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 155 | $107.64 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 949 | $103.57 |
| 73130 | <1% | 15 | $89.00 | |
| 87210 | <1% | 54 | $57.09 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 386 | $51.01 |
| 83605 | <1% | 612 | $47.16 | |
| 85610 | <1% | 600 | $25.78 | |
| 81003 | <1% | 323 | $25.09 | |
| 72100 | <1% | 17 | $24.05 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 186 | $14.88 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 383 | $13.40 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 12 | $4.30 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 218 | $2.61 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 848 | $0.00 |
| 74018 | 0% | 48 | $0.00 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 205 | $0.00 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 107 | $0.00 |
| 82948 | 0% | 530 | $0.00 | |
| 87631 | 0% | 151 | $0.00 | |
| 81025 | 0% | 728 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 242 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 84 | $0.00 |
| 84702 | 0% | 57 | $0.00 | |
| 94726 | 0% | 29 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 63 | $0.00 |
| 87186 | 0% | 54 | $0.00 | |
| 99152 | 0% | 14 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 89 | $0.00 |
| 11721 | 0% | 26 | $0.00 | |
| J0897 | Injection, denosumab, 1 mg | 0% | 12 | $0.00 |
| 82565 | 0% | 28 | $0.00 | |
| 93017 | 0% | 13 | $0.00 | |
| 84145 | 0% | 41 | $0.00 | |
| 86900 | 0% | 74 | $0.00 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 12 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 20 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 153 | $0.00 |
| 82043 | 0% | 59 | $0.00 | |
| 82550 | 0% | 54 | $0.00 | |
| 85730 | 0% | 123 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 81 | $0.00 |
| 87205 | 0% | 16 | $0.00 | |
| 97535 | Self-care/home management training, each 15 minutes | 0% | 120 | $0.00 |
| 83880 | 0% | 127 | $0.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 260 | $0.00 |
| 96376 | 0% | 258 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 2,356 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 26 | $0.00 |
| 85652 | 0% | 92 | $0.00 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 43 | $0.00 |
| 85379 | 0% | 80 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 78 | $0.00 |
| G0009 | Administration of pneumococcal vaccine | 0% | 13 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 256 | $0.00 |
| 87077 | 0% | 12 | $0.00 | |
| 86901 | 0% | 74 | $0.00 | |
| 87040 | 0% | 75 | $0.00 | |
| 90834 | Psychotherapy session, about 45 minutes | 0% | 124 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 13 | $0.00 |
| 92567 | 0% | 53 | $0.00 | |
| 82607 | 0% | 12 | $0.00 | |
| 87070 | 0% | 19 | $0.00 | |
| 80050 | General health panel | 0% | 15 | $0.00 |
| J3230 | Injection, chlorpromazine hcl, up to 50 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORRISON, TONY (VICE PRESIDENT, REVENUE CYCLE)
| Provider | Location | Paid |
|---|---|---|
| Sanford Medical Center Fargo | Fargo, ND | $50.18M |
| Sanford Health of Northern Minnesota | Bemidji, MN | $47.45M |
| Sanford Bismarck | Bismarck, ND | $43.96M |
| Sanford Health of Northern Minnesota | Bemidji, MN | $27.11M |
| Sanford Medical Center | Sioux Falls, SD | $24.40M |
| FM Ambulance Service, INC | Fargo, ND | $23.80M |
| Sanford Medical Center | Sioux Falls, SD | $18.03M |
| Sanford Health Network | Worthington, MN | $7.58M |
| Sanford Clinic | Sioux Falls, SD | $6.04M |
| Sanford Clinic | Sioux Falls, SD | $5.45M |
| Sanford Healthcare Accessories, LLC | Fargo, ND | $4.79M |
| Sanford Health Network North | Thief River Falls, MN | $3.28M |
| Sanford Clinic | Sioux Falls, SD | $2.96M |
| Sanford Health Network | Jackson, MN | $2.81M |
| Sanford Clinic | Watertown, SD | $2.02M |
| Black Hills Orthopedic & Spine Center, INC. | Rapid City, SD | $1.71M |
| Sanford Health Network | Chamberlain, SD | $1.47M |
| Sanford Health Network | Vermillion, SD | $1.31M |
| Sanford Health Network | Luverne, MN | $1.27M |
| Sanford Medical Center Fargo | Pelican Rapids, MN | $1.01M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.